Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 69 of 69 entries
View as:

Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01337505 Org: User:
Start: 04/30/11 End: 12/31/12 Due: 12/31/13

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

Phase: N/A Priority: Normal
NCT ID: NCT04050709 Org: User:
Start: 07/18/19 End: 12/30/24 Due: 12/30/25

QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

Phase: N/A Priority: Normal
NCT ID: NCT03520686 Org: User:
Start: 05/18/18 End: 04/01/26 Due: 04/01/27

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT03563144 Org: User:
Start: 08/31/18 End: 02/09/22 Due: 02/09/23

Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis

Phase: N/A Priority: Normal
NCT ID: NCT06040918 Org: User:
Start: 10/04/23 End: 09/03/24 Due: 09/03/25

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03197571 Org: User:
Start: 12/31/17 End: 12/28/21 Due: 12/28/22

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Phase: N/A Priority: Normal
NCT ID: NCT06800963 Org: User:
Start: 05/31/25 End: 02/29/28 Due: 02/28/29

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT06765954 Org: User:
Start: 06/01/25 End: 06/30/31 Due: 06/30/32

COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA

Phase: N/A Priority: Normal
NCT ID: NCT04732468 Org: User:
Start: 02/24/21 End: 01/09/23 Due: 01/09/24

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04390399 Org: User:
Start: 07/21/20 End: 10/31/25 Due: 10/31/26

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT03228667 Org: User:
Start: 12/11/18 End: 12/31/30 Due: 12/31/31

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06829823 Org: User:
Start: 05/01/25 End: 05/01/29 Due: 05/01/30

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03167177 Org: User:
Start: 12/31/17 End: 12/28/21 Due: 12/28/22

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03167164 Org: User:
Start: 12/31/17 End: 12/28/21 Due: 12/28/22

QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04898543 Org: User:
Start: 06/21/21 End: 05/31/25 Due: 05/31/26

QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04052061 Org: User:
Start: 09/16/19 End: 08/19/22 Due: 08/19/23

Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01673438 Org: User:
Start: 07/31/12 End: 04/30/14 Due: 04/30/15

ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06745908 Org: User:
Start: 05/31/25 End: 01/31/29 Due: 01/31/30

THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines

Phase: N/A Priority: Normal
NCT ID: NCT05370040 Org: User:
Start: 05/05/22 End: 03/11/24 Due: 03/11/25